- Current treatment goals are achieved by the majority of patients with atopic dermatitis treated with tralokinumab: results from a multicentric, multinational, retrospective, cohort study2023 | Third Faculty of Medicine
- Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study2015 | First Faculty of Medicine